Efficacy of Inactivated Split‐Virus Influenza Vaccine against Culture‐Confirmed Influenza in Healthy Adults: A Prospective, Randomized, Placebo‐Controlled Trial

Abstract

ClinicalTrials.gov identifier: NCT00363870.

Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial

“…Here, we describe the use of a real-time PCR (rtPCR) assay 8 in conjunction with virus culture in a prospective influenza vaccine efficacy study. 14 …”

Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine

“…Non-inferiority of the newly-licensed vaccine in the elderly (≥65 years) was determined in the same way (secondary analysis). The primary immunogenicity analysis was based on the according to protocol (ATP) cohort, which included all evaluable subjects for whom post-vaccination assay results for antibodies the newly-licensed vaccine, 31 all US regulatory requirements for licensure of the new vaccine for use in adults have been completed.…”

Cost effectiveness of influenza vaccination for specific populations in Iran

“…For the healthcare workers group, we calculated a pooled estimate of vaccine efficacy amongst 10 studies [8][9][10][11][12][13][14][15][16][17] for healthy adults aged 18-49 and results of the meta-analysis showed that pooled estimate of vaccine efficacy was equal to 66% (CI: 60-72) and there was heterogeneity between the results of the studies (Q = 13.69, P = 0.250). Regarding the school-age children, 2 studies [18,19] were included and pooled estimate of the vaccine efficacy was 64% (CI: 51-76).…”